Kenyon Secures Victory in Copaxone® Hatch Waxman Patent Litigation

New York, June 25, 2012 -- Kenyon & Kenyon LLP client Teva Pharmaceuticals won consolidated Hatch-Waxman patent litigations on June 22, 2012 in Teva Pharmaceuticals USA, Inc. et al v. Mylan Pharmaceuticals Inc. et al, 1:09-cv-08824-BSJ.  The litigation pertains to proposed generic equivalents to Teva's blockbuster multiple sclerosis drug Copaxone®.  Following trial, the Honorable Barbara S. Jones of the Southern District of New York rejected challenges to Teva’s patents, finding that “the Defendants', Mylan Pharmaceuticals Inc., et al. and Sandoz, Inc. et al., abbreviated new drug applications infringe all of the asserted claims of the Plaintiffs' patents and that none of the asserted claims are invalid or unenforceable.”   

As released by the former Kenyon & Kenyon LLP.